Apogee Therapeutics reports positive Phase 2 eczema trial data

Apogee Therapeutics (NASDAQ:APGE) reported positive mid-stage clinical data for its experimental eczema treatment, paving the way for late-stage trials later this year alongside a new multi-indication financing deal with Blackstone Life Sciences.

The biotechnology company announced that Part B of its Phase 2 APEX trial evaluating zumilokibart in patients with moderate-to-severe atopic dermatitis met all primary and secondary endpoints with high statistical significance.

Specifically, 65.9% of patients who received the optimized mid-dose version of the subcutaneous antibody achieved at least a 75% reduction in disease severity, measured by the Eczema Area and Severity Index (EASI-75).

By comparison, 23.4% of patients in the placebo group reached the same milestone.

Backed by these dose-optimization results, Apogee plans to advance the mid-dose regimen into Phase 3 clinical trials during the second half of 2026.

The company reported that the safety and tolerability profile of zumilokibart remained favorable and generally consistent with other biologic therapies within the same class of interleukin-13 inhibitors.

In tandem with the clinical results, Apogee secured a new strategic financing collaboration with Blackstone Life Sciences.

The funding package is structured to support the drug's clinical development through potential regulatory approval and commercialization across multiple targeted medical conditions.